Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Fineline Cube May 7, 2026
Company Drug

Akeso’s Ivonescimab Shows Promising Results in Phase III Clinical Trial for Hepatocellular Carcinoma

Fineline Cube Sep 9, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced that its first-in-class...

Company Legal / IP

AstraZeneca Faces Investigation in China Over Data Privacy and Unapproved Drugs

Fineline Cube Sep 6, 2024

AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, is reportedly under the spotlight in Shenzhen,...

Company Policy / Regulatory

U.S. House of Representatives to Review the Biosecure Act Amid Legislative Hurdles

Fineline Cube Sep 6, 2024

The U.S. House of Representatives is slated to take up the contentious Biosecure Act the...

Company Deals

Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery

Fineline Cube Sep 6, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Company

Euroapi to Downsize API Production, Citing Asian Competition and Market Stagnation

Fineline Cube Sep 6, 2024

Euroapi (EPA: EAPI), a French company and a spinoff from Sanofi established in 2022, has...

Company Deals

Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia

Fineline Cube Sep 6, 2024

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into...

Company Drug

Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial

Fineline Cube Sep 6, 2024

Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from...

Company Deals

Voyager Therapeutics Secures Licensing Deal with Novartis for Gene Therapy Capsid

Fineline Cube Sep 6, 2024

Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with...

Company Medical Device

Fujirebio’s HBsAg Detection Kit Receives NMPA Approval, Enhances Early Diagnosis Capabilities

Fineline Cube Sep 6, 2024

Fujirebio Inc., a leading diagnostic company based in Japan, has received approval from China’s National...

Company Drug

Jiangsu Kanion Pharmaceutical Gets NMPA Go-Ahead for Psoriasis Drug Clinical Trial

Fineline Cube Sep 6, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a prominent pharmaceutical company based in China, has...

Company Medical Device

Genesis MedTech Secures NMPA Approval for Innovative Surgical Energy Products

Fineline Cube Sep 6, 2024

Genesis MedTech, a leading medical device company headquartered in Singapore, has secured marketing approvals from...

Company Medical Device

True Health’s Advanced Microwave Ablation System Gains NMPA Nod for Liver Tumor Treatment

Fineline Cube Sep 6, 2024

True Health (Guangdong Hengqin) Medical Technology Co., Ltd has received marketing approval from China’s National...

Company Medical Device

Venus Medtech Initiates Global Study with Venus Vitae TAVR System Implantations

Fineline Cube Sep 6, 2024

Venus Medtech (Hangzhou) Inc., listed on the Hong Kong Stock Exchange as HKG: 2500, has...

Policy / Regulatory

China’s Hainan Free Trade Port Implements ‘Zero Tax’ on Medical Imports for Designated Entities

Fineline Cube Sep 6, 2024

In a joint effort to bolster healthcare services, China’s Ministry of Finance, National Health Commission...

Company Drug

Viatris Launches First-of-Its-Kind Nasal Spray Dymista in China for Allergic Rhinitis

Fineline Cube Sep 6, 2024

Viatris Inc. (NASDAQ: VTRS), a leading global pharmaceutical company based in the U.S., has announced...

Company Medical Device

Sansure Biotech Wins NMPA Nod for ALDH2 Gene Polymorphism Detection Kit

Fineline Cube Sep 5, 2024

Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...

Company Drug

Novo Nordisk Advances in China with Submission of Sogroya for Adult Growth Hormone Deficiency

Fineline Cube Sep 5, 2024

Denmark’s pharmaceutical heavyweight, Novo Nordisk (NYSE: NVO), has reached a significant milestone with the National...

Company

AstraZeneca China Restructures Biopharma Unit to Boost Chronic Disease Management

Fineline Cube Sep 5, 2024

AstraZeneca (NASDAQ: AZN)’s Chinese subsidiary has announced a strategic restructuring of its China biopharmaceutical business...

Company Drug

Kelun-Biotech’s ADC for Cancer Gets NMPA Review, Expands MSD Collaboration

Fineline Cube Sep 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has achieved a regulatory milestone with its clinical...

Company Deals R&D

Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments

Fineline Cube Sep 5, 2024

Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...

Posts pagination

1 … 296 297 298 … 661

Recent updates

  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
  • Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.